Human FcRn can mediate the transport across intestinal mucosal barrier and prolong the half-life of rabbit IgG in vivo

Pang, Guangchang; Xie, Junbo; Qing-sen, Chen; Zhi-he, HU

doi:10.1590/s1516-8913201500035

Cited by 1 publication

(1 citation statement)

References 23 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inhibition of FcRn up-regulation or the FcRn elimination pathway results in an increased elimination and prolongation of the half-life of an IgG [ 33 ] FcRn transports its ligands across a cellular monolayer providing a route for proteins into the blood stream (across the epithelial barriers) [ 34 ]. FcRn has been found in mucosal sites in adult mammalians and a number of studies have discussed the role of FcRn-mediated IgG in the intestine and gastrointestinal tract (GIT) [ 34 , 35 , 36 , 37 , 38 , 39 ]. The role of FcRn has also been described in pulmonary drug delivery [ 34 , 40 , 41 ], where the quantity and quality of IgG in the airways are regulated by FcRn [ 40 ].…”

Section: Introductionmentioning

confidence: 99%

Overview of Antibody Drug Delivery

2018

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) are one of the most important classes of therapeutic proteins, which are used to treat a wide number of diseases (e.g., oncology, inflammation and autoimmune diseases). Monoclonal antibody technologies are continuing to evolve to develop medicines with increasingly improved safety profiles, with the identification of new drug targets being one key barrier for new antibody development. There are many opportunities for developing antibody formulations for better patient compliance, cost savings and lifecycle management, e.g., subcutaneous formulations. However, mAb-based medicines also have limitations that impact their clinical use; the most prominent challenges are their short pharmacokinetic properties and stability issues during manufacturing, transport and storage that can lead to aggregation and protein denaturation. The development of long acting protein formulations must maintain protein stability and be able to deliver a large enough dose over a prolonged period. Many strategies are being pursued to improve the formulation and dosage forms of antibodies to improve efficacy and to increase the range of applications for the clinical use of mAbs.

show abstract